Navigation Links
Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
Date:3/19/2009

ASHBURN, Va., March 19 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the second of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections.

The trial is being conducted at approximately 45 hospital sites across the U.S. and has enrolled 600 patients undergoing open colorectal surgery, which is widely considered to be the most prone to surgical site infection (SSI). Patients in the treatment group have two Gentamicin Implants (260 mg total dose) implanted in the wound before abdominal closure and the primary endpoint is total incidence of SSI after 2 months post-surgery. The design of the trial is based upon an approved and well established use of GENTAMICIN SURGICAL IMPLANT for this indication in Europe. The results of several such studies have been published, including one prospective, randomized, controlled clinical trial in 221 patients which demonstrated a 70 percent decrease in surgical site infections from 18.4 percent in the control group to 5.6 percent in the patients treated with the implant.

Patient enrolment in the first phase 3 trial being conducted in diabetic and/or obese patients undergoing cardiac surgery closed earlier this month. Innocoll has appointed Duke University's Duke Clinical Research Institute (DCRI) as the Study Coordinating Center for both phase 3 trials.

Dr. Michael Myers, Innocoll's President and CEO commented, "Having recently completed patient enrollment in our first phase 3 trial in cardiac surgery, we are pleased to have now concluded enrollment in both trials, which FDA has confirmed are the only trials we need for NDA approval. As a well established product in Europe and other non-U.S. markets with proven safety, efficacy and pharm
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
2. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
5. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
7. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
9. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
10. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
11. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... addition of the "Micro Market Monitor: North ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is progressing steadily, which has resulted in fueling ... market. The main purpose of these dermatology devices ...
(Date:12/19/2014)... Calif., Dec. 18, 2014 Capnia, Inc. ... development of medical diagnostics based on its proprietary ... flow, today announced financial results for the third ... "Following the completion of our initial ... to maximize the recently initiated CoSense® commercial launch," ...
(Date:12/19/2014)... Since last month,s FBI shutdown of online ... the leading online black market for illegal drugs - ... offering of drugs and other illegal items.  New numbers ... succeed in lowering the numbers of drugs and illegal ... in August. But some new sites that have emerged ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3
... 2011 Raylene Riha and her husband, Michael, filed ... Johnson, Inc. seeking compensation for injuries caused by failures ... that have been recalled.  John David Hart of the ... Texas, is the attorney representing Raylene and Michael Riha ...
... (Tianjin) Co. Ltd, a leading research-based contract manufacturer of advanced ... the U.S. and China, is pleased to announce the recent ... Assurance as of March 1, 2011. Mr. ... the pharmaceutical industry (early and late stage), in quality assurance ...
Cached Medicine Technology:Law Offices of John David Hart: DePuy Recalled Hip Device Lawsuit Filed by Houston Woman 2Mr. Robert Andrews Joins Asymchem Life Science (Tianjin) Co. Ltd. as Vice President of Quality Assurance 2
(Date:12/22/2014)... (PRWEB) December 22, 2014 Fad diets ... changed. The reason why most fad diets have hung ... The problem with fad diets is that, as the body ... the dieter uncertain of how to reset the metabolism to ... reason, Diet Doc developed their all-inclusive diet plans ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The founders ... BLS and ACLS online certification provider, are proud to ... . The updated site now features a more user-friendly ... ever to use. , As a company spokesperson ... is now consolidated into a single page during the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... current Ebola virus epidemic are receiving further ... government agencies, nongovernmental organizations (NGOs) and other ... ongoing, healthcare workers, emergency responders, patients and ... such as the CmTP MediDefense system ...
(Date:12/22/2014)... Physicians in China are most eagerly ... of non-Hodgkin’s lymphoma (NHL), according to a new report ... consulting firm. MabThera is the only biologic available to ... form of NHL. , According to Kantar Health’s report, ... of NHL in China has been growing and is ...
(Date:12/22/2014)... OH (PRWEB) December 22, 2014 Explorys, ... three additions to its leadership team: Greg Yarrington as ... of Engineering, and Patrick Wells as Vice President of ... to add 80 new jobs in 2015 to support ... expansion of its platform-as-a-service offerings, and growth of its ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:ACLS Online Certification Website ACLS-PALS-BLS.com Now Features a New and User-Friendly Layout 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3
... at Wake Forest University Baptist Medical Center (WFUBMC) have discovered ... breast cancer. For the first time, a peptide found in ... of human breast tumors in mice, according to a study ... Patricia E. Gallagher, Ph.D., and E. Ann Tallant, Ph.D., scientists ...
... Hydrocephalus in Ugandan children and other developing countries is ... by previous bacterial infection, according to an international team ... believe that the best approach to this problem is ... grand medical mystery," said Steven Schiff, the Brush Chair ...
... , THURSDAY, Dec. 30 (HealthDay News) -- Certain ... a new study finds. Because of increasing urbanization, ... more than ever before. For example, foxes, raccoons and ... mice, rats, birds and other prey. For this ...
... , , , , , ... , AUDIO: Its not news ... Click here for more information. , ... , , , , , ...
... -- Researchers report that they,ve gained insight into the workings ... in how the body stores fat to protect against future ... be linked to both insulin sensitivity and the survival of ... all these different phenomena," Dr. Philipp Scherer, a professor of ...
... Reporter , THURSDAY, Dec. 29 (HealthDay News) -- As fears ... gripped much of the United States the past two winters, George ... As vice president of human resources for a Fort Lauderdale commercial ... and protect not only the company,s employees but also the tenants ...
Cached Medicine News:Health News:Peptide delivers 1-2 punch to breast cancer in pre-clinical study 2Health News:Infant hydrocephalus, seasonal and linked to farm animals in Uganda 2Health News:Infant hydrocephalus, seasonal and linked to farm animals in Uganda 3Health News:Infant hydrocephalus, seasonal and linked to farm animals in Uganda 4Health News:Consistent exercise associated with lower risk of colon cancer death 2Health News:Consistent exercise associated with lower risk of colon cancer death 3Health News:Research Sheds Light on 'Starvation Hormone' 2Health News:How One Company Fought the Flu 2
... a large body for increased stability ... centimeters center-to-center) to resist the wear ... indicators are molded into the body. ... bar electrode styles. Shielded bar electrodes ...
... Cadwell's custom bars have a ... solid, machined contacts (spaced 3 centimeters ... tear of repeated cleaning. Polarity indicators ... convenient, snap-on handle fits our bar ...
The Surgifresh mini has the same rugged construction as the Plume-inator. It is the ideal size for operating room, clinic and office settings. This unit includes a filter test button, hospital grade ...
... Evolutionary refractive lens technology for ... safety and efficacy, demonstrates quality of ... contact lens correction. The lens is ... and is now available for the ...
Medicine Products: